Abbonarsi

Impact of an emergency medicine pharmacist on door to needle alteplase time and patient outcomes in acute ischemic stroke - 09/12/21

Doi : 10.1016/j.ajem.2021.11.015 
Julia Barbour a, , Patricia Hushen b, George C. Newman b, Jennifer Vidal a
a Department of Pharmacy, Einstein Medical Center Philadelphia, Philadelphia, PA, United States 
b Department of Neurology, Einstein Medical Center Philadelphia, Philadelphia, PA, United States 

Corresponding author at: Department of Pharmacy, Einstein Medical Center Philadelphia, 5501 Old York Road, Philadelphia, PA 19141, United States.Department of PharmacyEinstein Medical Center Philadelphia5501 Old York RoadPhiladelphiaPA19141United States

Abstract

Purpose

Time is a critical metric in the emergency department (ED) for acute ischemic stroke and thrombolytic therapy. National guidelines have emphasized tracking time from stroke onset to treatment and decreasing door to needle (DTN) time [1, 2]. Multidisciplinary teamwork is encouraged but, there is limited evidence demonstrating the value of the pharmacist on the stroke response team. The goal of this study is to compare DTN times in the ED with or without a pharmacist at bedside and examine the impact on subsequent patient outcomes.

Methods

This was a single-center retrospective cohort study. Investigators identified patients who presented to the ED between August 2016 – May 2020 with signs of ischemic stroke and subsequently received intravenous alteplase. Patients were excluded if they refused alteplase or received alteplase off-campus before being transferred. Pharmacist documentation of clinical interventions was used to identify participation on the stroke response team. The primary outcome was median DTN time. Secondary outcomes included severity of deficits measured by the National Institutes of Health Stroke Scale (NIHSS), hospital length of stay (LOS), 90-day Modified Rankin Scale (mRS), incidence of intracranial hemorrhage (ICH), and inpatient all-cause mortality.

Results

Of the 164 patients included, 31 had an emergency medicine pharmacist at bedside (EMP group) and 133 did not (No EMP group). The median DTN time was significantly shorter at 35 min EMP [interquartile range (IQR) 29–44] vs 42 min No EMP [IQR 34–55]; p = 0.003. The number of cases achieving a DTN time of 30 min or less was significantly higher when a pharmacist was involved (35.5% vs.16.5%; p = 0.018) as well as the number of patients receiving alteplase within 45 min (80.7% vs. 57.1%; p = 0.015). NIHSS scores at discharge were lower in the EMP group (2 [IQR 0–5] vs. 4 [IQR 0–8.25]; p = 0.049). In patients with magnetic resonance imaging (MRI) confirmed stroke, a difference was not observed in the secondary outcomes.

Conclusion

Patients with an emergency medicine pharmacist as part of their stroke response team had significantly lower DTN times. A higher proportion of these cases met benchmark DTN times less than 45 min and 30 min. An emergency medicine pharmacist on a stroke response team has the potential to improve patient care.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Emergency medicine, Stroke, Fibrinolytic agents, Tissue plasminogen activator, Clinical pharmacy, NIHSS


Mappa


© 2021  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 51

P. 358-362 - Gennaio 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • A missed opportunity in the ED: Palliative care consult delays during inpatient admission
  • Leah Bright, Korie Zink, Eili Klein, Rebecca Wright, Gabe Kelen
| Articolo seguente Articolo seguente
  • Severe hypercalcemia requiring acute hemodialysis: A retrospective cohort study with increased incidence during the Covid-19 pandemic
  • Y. Bentata, M. Benabdelhak, I. Haddiya, N. Oulali, B. Housni

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.